HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): David R. Jones Thomas M. Daniel Chadrick E. Denlinger Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jones, D. R. Articles by Wick, M. R. Search for Related Content PubMed PubMed Citation Articles by Jones, D. R. Articles by Wick, M. R. Related Collections Lung - cancer

Ann Thorac Surg 2006;81:1958-1962
© 2006 The Society of Thoracic Surgeons

---

Original article: General thoracic

Stage IB Nonsmall Cell Lung Cancers: Are They All the Same?

^a Department of Surgery, University of Virginia School of Medicine, Charlottesville, Virginia
^b Department of Health Evaluation Sciences, University of Virginia School of Medicine, Charlottesville, Virginia
^c Department of Pathology, University of Virginia School of Medicine, Charlottesville, Virginia

Accepted for publication December 7, 2005.

^_* Address correspondence to Dr Jones, Thoracic and Cardiovascular Surgery, PO Box 800679, University of Virginia, Lee Street, 4th Floor, Suite 4823 Charlottesville, VA 22908-0679 (Email: djones{at}virginia.edu).

Presented at the Fifty-first Annual Meeting of the Southern Thoracic Surgical Association, Cancun, Mexico, Nov 2–4, 2004.

BACKGROUND: There is renewed interest in adjuvant chemotherapy after complete resection of nonsmall cell lung cancer, including stage IB (T2N0) cancers. Given the heterogeneity of the T2 classification, we hypothesize that there are survival differences in patients with stage IB NSCLC based on specific histopathologic tumor characteristics.

METHODS: A retrospective evaluation of 119 consecutive patients from 1999 to 2004 with a pathologic diagnosis of T2N0 nonsmall cell lung cancer was performed. Patient follow-up was 97%. Overall survival and disease-free survival rates were calculated by the Kaplan-Meier method. Univariate analysis was performed using the log rank test and multivariate analysis by Cox's proportional hazard model. Data were significant if p < 0.05.

RESULTS: The 4-year overall survival and disease-free survival rates were 62% and 60%, respectively. The local and distant recurrence rates were 5% and 18%, respectively. Tumor size (p = 0.001), histologic grade (p = 0.002), the Eastern Cooperative Oncology Group performance status (p = 0.002), angioinvasion (p = 0.03), and visceral pleural involvement (p = 0.02) were predictors of overall survival by univariate analysis. Multivariate analysis demonstrated increasing tumor size (1.26 [95% confidence intervals 1.12, 1.64]) and histologic grade (4.05 [95% confidence intervals 1.38, 11.90]) to be significant independent predictors of a worse overall survival. The 4-year survival of patients without any of these variables was 89% compared with 56% if one or more of these factors were present (p = 0.03).

CONCLUSIONS: There is significant heterogeneity in the T2N0 class of nonsmall cell lung cancer. Risk stratification using specific histopathologic variables may help determine which patients will benefit most from adjuvant therapy.

This article has been cited by other articles:

				S.-H. I. Ou, J. A. Zell, A. Ziogas, and H. Anton-Culver Prognostic Significance of the Non-Size-Based AJCC T2 Descriptors: Visceral Pleura Invasion, Hilar Atelectasis, or Obstructive Pneumonitis in Stage IB Non-small Cell Lung Cancer Is Dependent on Tumor Size Chest, March 1, 2008; 133(3): 662 - 669. [Abstract] [Full Text] [PDF]